Suven Pharma will acquire a majority stake in Sapala Organics, a CDMO specializing in oligonucleotides and nucleic acid building blocks. The initial agreement involves purchasing a 67.5 percent stake in Sapala, with plans to eventually acquire the entire company.
The strategic move highlights Suven’s commitment to expanding its presence in the rapidly growing oligonucleotides and nucleic acid building blocks market, which is valued at approximately $750 million.
Globally, Sapala is a known player due to its expertise in complex oligo building blocks. The acquisition aims to leverage Sapala’s unique competencies and Suven’s manufacturing expertise to create synergies and growth opportunities.
As reported by ManufacturingToday, Dr. P Yella Reddy, founder of Sapala, believes the partnership is promising and could lead to substantial growth and progress. With government approval, the deal is expected to enhance Suven’s portfolio and strengthen its position in the industry.
